Omnix Medical Secures $25 Million in Series C Funding Co-Led by Harel Insurance & Finance and the EIC Fund

Core Insights - Omnix Medical has successfully raised $25 million in a Series C funding round to support the development of its novel antimicrobials pipeline, addressing the urgent global need for resistance-proof treatments [1][2] - The funding will facilitate the completion of Phase II proof-of-concept studies for its lead compound, OMN6, which targets life-threatening infections caused by Gram-negative bacteria, particularly resistant strains [2][4] - OMN6 is a first-in-class antimicrobial peptide with a unique mechanism of action that disrupts bacterial cell membranes, showing promising preclinical and clinical results [3][6] Company Overview - Omnix Medical was founded in 2015 to combat the global crisis of drug-resistant bacterial infections and has received support from various institutions, including the Israeli Innovation Authority and the U.S. National Institutes of Health [5] - The company has raised a total of $43 million since its inception, indicating strong investor confidence in its innovative approach [2][5] Funding and Investor Support - The Series C funding round was co-led by Harel Insurance & Finance and the EIC Fund, with participation from existing shareholders and new investors, reflecting a strong belief in Omnix's mission [1][3] - The funding will also support regulatory activities, manufacturing scale-up, and the advancement of Omnix's broader pipeline of engineered antimicrobial peptides [2][3] Product Development - OMN6 has received Fast-Track and QIDP designations from the U.S. FDA, highlighting its potential as a critical treatment for multidrug-resistant infections [3] - The compound's engineered stability and rapid action are designed to minimize the likelihood of resistance development, positioning it as a transformative solution in the fight against resistant pathogens [4][6]